Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer

Nicholas Cheng, Kimberly Skead, Althaf Singhawansa, Tom W. Ouellette, Mitchell Elliott, David W. Cescon, View ORCID ProfileScott V. Bratman, Daniel D. De Carvalho, David Soave, Philip Awadalla
doi: https://doi.org/10.1101/2023.01.30.23285027
Nicholas Cheng
1Computational Biology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
2Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Skead
1Computational Biology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
2Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Althaf Singhawansa
4Department of Medicine, University of Toronto, Toronto, Ontario, Canada
5Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
6Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom W. Ouellette
1Computational Biology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
2Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitchell Elliott
4Department of Medicine, University of Toronto, Toronto, Ontario, Canada
5Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Cescon
4Department of Medicine, University of Toronto, Toronto, Ontario, Canada
5Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
6Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott V. Bratman
6Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
7Department of Medical Biophysics, University of Toronto, Ontario, Canada
8Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott V. Bratman
Daniel D. De Carvalho
6Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
7Department of Medical Biophysics, University of Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Soave
1Computational Biology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
3Department of Mathematics, Wilfrid Laurier University, Waterloo, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Awadalla
1Computational Biology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada
2Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
9Ontario Health Study, Ontario Institute for Cancer Research, Toronto, Canada
10Dalla Lana School of Public Health, University of Toronto, Ontario Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Philip.awadalla@oicr.on.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Profiling of cell-free DNA (cfDNA) has been well demonstrated to be a potential non-invasive screening tool for early cancer detection. However, limited studies have investigated the detectability of cfDNA methylation markers that are predictive of cancers in asymptomatic individuals. We performed cfDNA methylation profiling using cell-free DNA methylation immunoprecipitation sequencing (cfMeDIP-Seq) in blood collected from individuals up to seven years before a breast cancer diagnosis in addition to matched cancer-free controls. We identified differentially methylated cfDNA signatures that discriminated cancer-free controls from pre-diagnosis breast cancer cases in a discovery cohort that is used to build a classification model. We show that predictive models built from pre-diagnosis cfDNA hypermethylated regions can accurately predict early breast cancers in an independent test set (AUC=0.930) and are generalizable to late-stage breast cancers cases at the time of diagnosis (AUC=0.912). Characterizing the top hypermethylated cfDNA regions revealed significant enrichment for hypermethylation in external bulk breast cancer tissues compared to peripheral blood leukocytes and breast normal tissues. Our findings demonstrate that cfDNA methylation markers predictive of breast cancers can be detected in blood among asymptomatic individuals up to six years prior to clinical detection.

Competing Interest Statement

DDC and SVB are listed as co-inventors on patents filed related to the cfMeDIP-seq technology. SVB is co-inventor of a patent related to mutation-based ctDNA detection that is licensed to Roche. DDC received research funds from Pfizer and Nektar therapeutics. DDC and SVB are co-founders of, have ownership in, and serve in leadership roles at Adela. DWC has acted in a consulting/advisory role for AstraZeneca, Exact Sciences, Eisai, Gilead, GlaxoSmithKline, Inivata, Merck, Novartis, Pfizer and Roche, received research funding (to institution) from AstraZeneca, Gilead, GlaxoSmithKline, Inivata, Merck, Pfizer, and Roche and holds a patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. All the other authors declare no conflict of interest.

Funding Statement

OHS biological materials were stored at the Ontario Health Study Biobank, which is supported by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario, the Princess Margaret Cancer Foundation, and a Genome Canada grant (OGI-136) to PA. The OCTANE study was conducted with the support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario and by the Princess Margaret Cancer Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Patient plasma samples were obtained from the Ontario Health Study (OHS) with protocols approved by the University of Toronto Health Sciences research ethics board (protocol #34088). All participants gave written informed consent prior to participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

  • Abbreviations

    ABRNM
    Adjacent Breast Normal
    AUC
    Area Under the Receiver Operating Characteristic Curve
    AUC(t)
    Time-dependent Area Under the Receiver Operating Characteristic Curve
    HBRNM
    Healthy Breast Normal
    BRCA
    Breast Cancer
    cfDNA
    Cell-free DNA
    C-index
    Concordance Index
    CoxPH
    Cox Proportional Hazard
    CV
    Cross-validation
    DMR
    Differentially Methylated Regions
    GEO
    Geo Expression Omnibus
    IC
    Input Control Library
    IHEC
    International Human Epigenetics Consortium
    IP
    Input Library
    KM
    Kaplan-Meier
    LogFC
    Log Fold-Change
    OCTANE
    Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
    OHS
    Ontario Healthy Study
    TCGA
    The Cancer Genome Atlas
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
    Back to top
    PreviousNext
    Posted February 01, 2023.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer
    Nicholas Cheng, Kimberly Skead, Althaf Singhawansa, Tom W. Ouellette, Mitchell Elliott, David W. Cescon, Scott V. Bratman, Daniel D. De Carvalho, David Soave, Philip Awadalla
    medRxiv 2023.01.30.23285027; doi: https://doi.org/10.1101/2023.01.30.23285027
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Pre-diagnosis plasma cell-free DNA methylome profiling up to seven years prior to clinical detection reveals early signatures of breast cancer
    Nicholas Cheng, Kimberly Skead, Althaf Singhawansa, Tom W. Ouellette, Mitchell Elliott, David W. Cescon, Scott V. Bratman, Daniel D. De Carvalho, David Soave, Philip Awadalla
    medRxiv 2023.01.30.23285027; doi: https://doi.org/10.1101/2023.01.30.23285027

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (227)
    • Allergy and Immunology (500)
    • Anesthesia (110)
    • Cardiovascular Medicine (1230)
    • Dentistry and Oral Medicine (205)
    • Dermatology (147)
    • Emergency Medicine (282)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (529)
    • Epidemiology (10005)
    • Forensic Medicine (5)
    • Gastroenterology (497)
    • Genetic and Genomic Medicine (2445)
    • Geriatric Medicine (236)
    • Health Economics (479)
    • Health Informatics (1635)
    • Health Policy (751)
    • Health Systems and Quality Improvement (633)
    • Hematology (248)
    • HIV/AIDS (531)
    • Infectious Diseases (except HIV/AIDS) (11855)
    • Intensive Care and Critical Care Medicine (625)
    • Medical Education (251)
    • Medical Ethics (74)
    • Nephrology (267)
    • Neurology (2273)
    • Nursing (139)
    • Nutrition (350)
    • Obstetrics and Gynecology (452)
    • Occupational and Environmental Health (532)
    • Oncology (1244)
    • Ophthalmology (375)
    • Orthopedics (133)
    • Otolaryngology (226)
    • Pain Medicine (154)
    • Palliative Medicine (50)
    • Pathology (324)
    • Pediatrics (729)
    • Pharmacology and Therapeutics (311)
    • Primary Care Research (282)
    • Psychiatry and Clinical Psychology (2280)
    • Public and Global Health (4824)
    • Radiology and Imaging (833)
    • Rehabilitation Medicine and Physical Therapy (488)
    • Respiratory Medicine (650)
    • Rheumatology (283)
    • Sexual and Reproductive Health (237)
    • Sports Medicine (225)
    • Surgery (266)
    • Toxicology (44)
    • Transplantation (124)
    • Urology (99)